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Phase Composition Control of Calcium Phosphate Nanoparticles
for Tunable Drug Delivery Kinetics and Treatment of
Osteomyelitis. Part 1: Preparation and Drug Release
Vuk Uskoković and Tejal A. Desai
Therapeutic Micro and Nanotechnology Laboratory, Department of Bioengineering and
Therapeutic Sciences, University of California, San Francisco

Abstract
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Developed in this study is a multifunctional material for simultaneous osseoinduction and drug
delivery, potentially applicable in the treatment of osteomyelitis. It is composed of agglomerates
of nanoparticles of calcium phosphate (CAP) with different monophasic contents. The drug
loading capacity and the release kinetics were investigated on two model drug compounds with
different chemical structures, sizes and adsorption propensities: bovine serum albumin and
fluorescein. Loading of CAP powders with small molecule drugs was achieved by physisorption
and desiccation-induced agglomeration of nanoparticulate subunits into microscopic blocks. The
material dissolution rate and the drug release rate depended on the nature of the CAP phase,
decreasing from monocalcium phosphate to monetite to amorphous CAP and calcium
pyrophosphate to hydroxyapatite. The sustained release of the two model drugs was shown to be
directly relatable to the degradation rate of CAP carriers. It was demonstrated that the degradation
rate of the carrier and the drug release kinetics could be made tunable within the time scale of 1–2
h for the most soluble CAP phase, monocalcium phosphate, to 1–2 years for the least soluble one,
hydroxyapatite. From the standpoint of antibiotic therapy for osteomyelitis, typically lasting for
six weeks, the most prospective CAP powder was amorphous CAP with its release time scale for a
small organic molecule, the same category to which antibiotics belong, of 1 – 2 months under the
conditions applied in our experiments. By combining these different CAP phases in various
proportions, drug release profiles could be tailored to the therapeutic occasion.

Introduction
NIH-PA Author Manuscript

Nanomedical approaches are based on finely tuned and localized therapies that overcome
many of the undesired side effects resulting from nonlocal distribution of therapeutic agents
in the body.1 Procedures for the synthesis of nanoparticles of practically every known
composition have been developed over the past few decades2, and the challenge ahead of us
currently lies in preparation of multifunctional composite nanoparticulate systems.3 The
approach pursued in this study is based on the hypothesis that the development of a
multifunctional nanoparticulate system that could simultaneously foster remineralization of
the portion of bone lost to disease and release antibiotics at a finely tunable rate would
improve the treatment of osteomyelitis.
Osteomyelitis, that is, bone infection caused by a variety of pathogens4, many of which
reside in healthy oral flora, affects mainly elderly and children and has been conventionally
treated by means of (a) long-term antibiotic therapies5, and (b) surgical removal of the
portion of necrotic bony tissue6. While systemic distribution of the therapeutics in the body
results from the former approach, the latter typically requires the application of extraneous
implants to maintain the skeletal integrity of the affected area and/or minimize the effects of
its unaesthetic disfigurement. Clear incentives thus exist for the development of more
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advanced therapies based on (a) local and sustained delivery of antibiotics, and (b)
osteogenic drug carriers.

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Calcium phosphates (CAPs) have been traditionally considered as a suitable choice for the
synthetic substitute of hard tissues due to their excellent biocompatibility, lack of
cytotoxicity, non-immunogenicity, non-onconogenicity as well as sufficient loading
capacities7. Hydroxyapatite (HAP), a CAP phase naturally present in hard tissues, is the
most stable one under physiological conditions; however, the downside of this exceptional
chemical stability and sufficient compressive strength of HAP is its rather slow resorption
kinetics8. The second most commonly used CAP phase is tricalcium phosphate (TCP);
however, its degradation rate is thought to be too high to match the new bone growth rate9.
Optimization of the phase composition of CAP used for bone grafting purposes has
consequently grown into a conventional approach to improving the biodegradability of
CAP-based biomaterials while preserving their strength during the past three decades10,11.
Most of these materials have, however, been composed of mainly two phases: HAP and
TCP12. Yet, as can be seen from Table 1, solubility of CAPs can be optimized within a wide
range of values, from highly soluble monocalcium phosphates (pKsp = 1.14) to sparsely
soluble HAP (pKsp = 117.3). In this work, we have focused on assessing solubility behavior,
along with the drug release profiles, of a few rarely used CAP phases, including HAP.
Starting from the assumption that the drug release rate can be made directly proportional to
the degradation rate of the particles encapsulating the drug, optimization of the latter by
means of controlling the stochiometry of the drug delivery carrier has been the approach
followed in this study.

Experimental part
Synthesis of CAP powders
CAP powders with various monophase compositions were prepared by direct precipitation
from aqueous solutions, as described by the following reaction:
(Eq.1)

(Eq.1)
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The method for preparation of HAP was adapted and modified from Ref.17. It began with
adding 400 ml of 0.06 M aqueous solution of NH4H2PO4 containing 25 ml 28 % NH4OH
dropwise (13.333 ml/min) to the same volume of 0.1 M aqueous solution of Ca(NO3)2
containing 50 ml 28 % NH4OH, vigorously stirred with a magnetic bar (400 rpm) and kept
on a plate heated to 50 °C. After the addition of NH4H2PO4 was complete, the suspension
was brought to boiling, then immediately removed from the heater and let cool in air.
Stirring was suspended and the precipitate alongside its parent solution was left to age in
atmospheric conditions for 24 h. After the given time, the precipitate was washed once with
deionized (DI) H2O, centrifuged (10 sec at 3500 rpm), and let dry overnight in a vacuum
oven (p = − 20 mmHg) at 80 °C.
To synthesize monetite (dicalcium phosphate anhydrous; DCPA, CaHPO4), the same
procedure was repeated using 400 ml 0.33 M Ca(NO3)2 and 400 ml 0.25 M NH4H2PO4
containing 10 ml 28 % NH4OH, with bringing the suspension to boiling afterwards. To
synthesize calcium pyrophosphate (CPP, β-Ca2P2O7), the same procedure was repeated
using the same volumes of 0.2 M Ca(NO3)2 containing 3 ml of 28 % NH4OH and 0.25 M
NH4H2PO4 supplemented with 28 % NH4OH until pH 6.8 was reached. Following
precipitation and drying, the loose powder was annealed in a Barnstead Thermolyne 1300
furnace at 800 °C for 2 h, with the heating and cooling rates of 10 °C/min.
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The synthesis of monocalcium phosphate monohydrate (Ca(H2PO4)2·H2O, MCPM) was
carried out by mixing identical volumes of 3.5 M H3PO4 (40 wt% conc. H3PO4) and 1.8 M
Ca(NO3)2. The transparent mixture was intensively agitated using a magnetic bar and
brought to boiling. When approximately two-thirds of the liquid evaporated, the
precipitation occurred and a white suspension was formed. Stirring was immediately
discontinued, lest DCPA formed due to extensive evaporation. The sol was let cool down
and turn into a gel at room temperature. To prevent precipitation at a very high
supersaturation when the precipitate solidifies and becomes virtually unsuspendable, the
temperature of the heating plate did not exceed 250 °C. The gel was repeatedly alternately
centrifuged and washed with ethanol to remove H3PO4, separated from the supernatant,
dried for 30 min at room temperature and stored at 4 °C to prevent transformation to DCPA.
Amorphous CAP (ACP) was formed by abruptly adding a solution containing 100 ml 0.5 M
Ca(NO3)2 and 7 ml 28 % NH4OH into a solution comprising 100 ml 0.2 M NH4H2PO4 and
4 ml 28 % NH4OH. The fine precipitate formed upon mixing was aged for 15 s, before it
was collected, centrifuged, washed with 0.14 w/v% NH4OH, centrifuged again, dried
overnight at low pressure (p = − 20 mmHg) and room temperature, and stored at 4 °C to
prevent spontaneous transformation to HAP. Table 2 lists ionic concentrations and pHs of
Ca(NO3)2 and NH4H2PO4 solutions prior to their mixing, along with the final pH of the
solution in equilibrium with the precipitate and the crystallite size of such obtained powders.
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CAP solubility experiments
Solubility of synthesized CAP powders was evaluated in a twofold manner. First, 10 mg of
each CAP powder, except MCPM, were placed in separate 10 ml of either 20 mM Tris/HCl
(pH 7.4) or 20 mM MES/NaCl (pH 6.0) and incubated at room temperature. For MCPM, 10
times higher concentration of the buffers was used to prevent pH drop due to a considerable
release of free protons and HPO42−/H2PO4− ions upon its dissolution. The concentration of
free calcium ions in the solution ([Ca2+]) was read periodically using Ca2+ microelectrode in
combination with a reference electrode (Microelectrodes, Inc.) on an Accumet AR15 pHmeter (Fisher Scientific). The solution was replaced every 24 h to prevent saturation and
minimize the effects of spontaneous re-precipitation. The average dissolution rate was
calculated as:
(Eq. 2)

(Eq. 2)
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[Ca]t2 and [Ca]t1 represent two measured concentrations of free Ca2+ ions at two successive
time points; n is the number of data points; t2 and t1 stand for two successive time points;
and [Ca2+]total equals the total concentration of free Ca2+ ions upon complete dissolution of
the powder. The second dissolution test involved placing 10 mg of each CAP powder,
except MCPM, in separate 10 ml of 20 mM Tris/HCl (pH 7.4) solution and incubation at
room temperature. As in the first dissolution test, MCPM was immersed in 200 mM Tris/
HCl (pH 7.4). The acidic solution of 2 M HCl was added in increments of 1 – 10 µl to
gradually lower the pH. After 5 min of incubation at each pH, [Ca2+] was read using Ca2+
microelectrode in combination with a reference electrode. The degree of saturation (DS) was
calculated using an algorithm based on Debye-Hückel equation18.
Drug loading and release
To test the drug loading efficiency and release kinetics, CAP particles with different phase
compositions were loaded by physisorption with a moderately sized polypeptide,
fluorescein-isothiocyanate-tagged bovine serum albumin (FITC-BSA; 66.5 kDa; 14 × 4 × 4
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nm3, Sigma), and a small organic molecule, fluorescein sodium (C20H10Na2O5; logP = 3.4;
Mw = 376.28 g/mol, d ~ 0.7 nm, Fluka). The latter compound was chosen due to its
similarity in size and hydrophilicity to clindamycin (C18H33ClN2O5S; logP = 1.6; Mw = 424
g/mol), the antibiotic loaded in the later stages of the study. More details about the loading
procedure are given in the supplementary section. Drug release experiments were conducted
by immersing 10 mg of each CAP powder separately in 1 ml of 20 mM Tris/HCl (pH 7.4)
and incubating them at room temperature for up to 10 days. A portion of the solution (100
µl) was sampled out periodically and analyzed for fluorescence convertible to concentration.
The medium was replaced every 24 h to prevent saturation and minimize spontaneous reprecipitation. At the end of the 200 h release time, the remaining powders were dissolved in
20 mM HCl. The resulting fluorescence was measured and used to calculate the overall
amount of the drug initially contained by the powders. The dissolution and the consequential
drug release amounts settled under these measurement conditions already after 24 – 48 h,
allowing for extrapolation of the given values from the known average daily amounts of the
dissolved powder or a released drug and eliminated the necessity for long-term
measurements.
Structural and morphological characterization

NIH-PA Author Manuscript

X-ray diffraction (XRD) studies were carried out on a Siemens D500 diffractometer using
CuKα = 1.5418 Å as the wavelength of the radiation source. The average size of the
crystallites was determined using a structural refinement approach (Topas 2.0) based on the
previously identified crystal structure (PCPDFWIN & Eva). The step size was 0.04 °, with 1
s of sample irradiation time per step. The morphology of the powders was analyzed on a
Hitachi S-4300SE/N scanning electron microscope (SEM) equipped with an energy
dispersive X-Ray (EDX) analyzer at the electron beam energy of 15 kV. Zeta-potential
values in the pH range of 4 – 10 were measured in water using a Malvern Zetasizer Nano
Series.

Results and Discussion

NIH-PA Author Manuscript

Literature reports on using CAPs as drug delivery carriers have been steadily increasing over
years.19–23 On the other hand, studies aimed at developing CAP particles for tunable drug
release have been far less numerous.24–26 Moreover, most of them focused on release of
proteins, compounds that much more efficiently adsorb onto mineral surface than small
organics, the category into which antibiotics fall. In this work, we decided to focus on five
different monophasic compositions of CAPs, covering their entire range of solubility
products, from pKsp 1 to 117 (Fig.1a). XRD patterns of the prepared monophasic CAP
powders are shown in Fig.1b. Some phases were omitted: OCP due to (a) the proximity of
its Ksp to that of HAP (Table 1) and (b) the fact that it is a metastable polymorph that tends
to spontaneously transform to HAP with an increase of the reaction temperature or time27,28;
TCP owing to (a) the fact that calcination, during which sintering of grains often occurs29, is
required for its formation, and (b) the proximity of its Ksp to Ksp reported for various forms
of ACP obtained under similarly alkaline conditions of precipitation as those used in this
study (Table 1).
Ideally, a single synthesis parameter would be varied for the sake of controlling the phase
composition of precipitated CAP powders and tuning their solubility over a wide range of
values. However, this approach did not prove to be viable in reality, as in accordance with
the need to apply different methods of precipitation to obtain different CAP phases outlined
by Hodge et al. in 1938: “The composition of the precipitated phosphates is seen to depend
upon the mode of precipitation rather than the amount of reactants”30. Correspondingly, a
variation of pH in the method used to precipitate HAP was shown to yield only DCPA at pH
< 6 when precipitation was carried out at 50 °C (Fig.2a) and at pH ≤ 5 when CAP sol was
J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.
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brought to boiling following its precipitation (Fig.2b). Also, a simple variation of Ca/P
molar ratio, which increases in more or less direct proportion with pKsp (Table 1), yielded
HAP powders with identical XRD patterns and unmodified crystallite sizes (12 nm) and
morphologies. Variations in the rate of addition of the precursor NH4H2PO4 solution to
Ca(NO3)2 were earlier shown to affect only the stoichiometry of the resulting CAP powders,
but not their phase composition.31 Different methods thus had to be used to obtain different
CAP phases: precipitation from solutions with low degrees of saturation and high Ca/P
ratios was applied in the synthesis of HAP and DCPA; abrupt mixing of reactants that
produced conditions of ultrahigh supersaturation and nucleation rate was used to prepare
ACP; evaporation of solutions at low pH and low Ca/P ratios was used in the formation of
MCPM; annealing of a precipitated mixture of DCPA and HAP at a moderately high
temperature was applied to yield CPP.

NIH-PA Author Manuscript

The size of HAP and DCPA crystallites corresponding to XRD patterns in Fig.2 was in the
nano range: 30 – 60 nm for DCPA and 5 – 17 nm for HAP synthesized directly, without
bringing the colloidal suspension to boiling, and 50 – 90 nm for DCPA and 3 – 12 nm for
HAP whose preparation was coupled to the boiling step. In general, whereas boiling
promoted an increase in the crystallite size for DCPA, it had an opposite effect for HAP. In
the case of DCPA, boiling was shown to be necessary to prevent coalescence of the particles
and retain the nanoparticulate nature of the precipitate. The monodisperse and nanosized
nature of DCPA powder prepared using boiling (Fig.3a) differs from smooth microsized
plates formed when the boiling step is omitted (Fig.3b). Since precipitation of CAP is an
endothermal process32,33, an increase in temperature will, according to Le Châtelier’s
principle, yield lower solubility and greater supersaturation. Consequently, boiling leads to
completion of the solidification process and prevents the ripening effect and formation of
layered structures, such as those displayed in Fig.3b. The final pH of the precipitation
reaction had an effect on the crystallite size, but only in the case of as-precipitated powders
(Fig.2a): the lower it was during the formation of DCPA, the greater the crystallinity of the
powder, while the opposite trend was observed for HAP. In contrast, when boiling was
applied following precipitation, there was no variation in the crystallinity of the powders
depending on the pH (Fig.2b).
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SEM images of HAP and other CAP powders are shown in Fig.3. The morphological
analysis of CAP samples indicates their unequivocally spherical and nanosized character.
The particle size was found in the range from 20 – 100 nm for the non-annealed phases,
HAP, ACP, DCPA and MCPM, to 100 – 300 nm for the only annealed phase, CPP. In the
case of MCPM, the nanoparticles exhibited a tendency to aggregate into plates of 1 – 3 µm
in length and 100 – 200 nm in thickness (Fig.3e). To ensure that CPP powder retained the
nanoparticulate nature of its precipitated precursor, annealing of comparatively low intensity
was used for its formation: 800 °C for 2 h (Fig.S1). This phase was chosen over TCP,
another CAP phase obtainable strictly through calcinations, because of its significantly
higher proneness to bioresorption34, upon which the drug release is expected to be directly
contingent.
Results of the tests designed to assess the solubility of different CAP phases at two different
pHs, the physiological (7.4) and the mildly acidic one (6.0), are shown in Fig.4. At both
pHs, the highest solubility was expectedly exhibited by MCPM, as in 1–2 h the dissolution
of the material reached completion. The dissolution process still took place not
instantaneously, but gradually under static conditions of incubation applied in the tests. The
second highest solubility was exhibited by DCPA, as it took approximately a week for it to
completely dissolve at pH 7.4 and 2–3 weeks at pH 6.0. As in agreement with the
stochiometric solubility data (Table 1), the solubility of ACP was lower than that of DCPA,
but higher than that of HAP. If extrapolated along the time axis, it could be shown that
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dissolution of ACP at pH 7.4 would be over in about 3 months, as opposed to a year in the
case of HAP, all under the solubility measurement settings based on daily replacement of the
solution and the given concentration of the solid phase (1 mg/ml). If extrapolation of values
obtained only during the first hour of dissolution following medium replacement at pH 7.4 is
carried out, the estimated time until total dissolution becomes lower for all phases except
MCPM: 2 months for HAP, 1 week for ACP, and 10 h for DCPA. As dictated by the
thermodynamic propensities of HAP, its solubility is greater at pH 6.0 than at pH 7.4,
although negligibly, increasing from 0.25 to 0.3 % per day. Extrapolation of values obtained
only during the first hour of dissolution following medium replacement at pH 6.0 again
yields lower estimated times until total dissolution for all phases except MCPM: 2 months
for HAP, 2 weeks for ACP, and 3 days for DCPA. Overall, the comparison of solubilities at
two different pHs has yielded the following insights: MCPM has not shown significant
difference in solubility behavior depending on the pH; alkaline ACP and HAP have
expectedly demonstrated increased solubility at the lower pH; DCPA, owing to the presence
of a proton in its stoichiometric formula and, consequently, a greater stability under mildly
acidic conditions, has shown higher resistance to dissolution at pH 6.0 than at pH 7.4. Table
3 compiles the data on dissolution time scales and rates for four different CAP powders.
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The dissolution of CPP was shown to exhibit the lowest initial burst in dissolved material
(Fig.4c). The reason for this presumably lies in its much lesser content of amorphized and
easily soluble material on the particle surface compared to as-precipitated powders. The
initial dissolution rate was much higher for ACP and HAP, which is, conversely, most likely
caused by the relatively disordered particle surface of as-precipitated solids, which
entropically favors their dissolution in comparison with the more crystalline particle core.
After only a few hours of dissolution, however, the dissolution rate of CPP stabilizes and
maintains an identical value as that of ACP throughout the rest of the incubation time. Due
to this identicality, CPP was exempted from the subsequent drug release studies. The
dissolution rate for CPP at pH 7.4 was found to be 0.8 % per day, while time to its complete
dissolution was equal to that of ACP, i.e., approximately 3 months, or about 2 weeks, double
that of ACP, when the results were extrapolated for 1 h medium replacement. During the
dissolution of HAP and ACP, the amount of the dissolved solid phase drastically drops
down after a few initial sets of medium replacements (Fig.S3). This effect is consistent with
the regularly observed incongruent, nonstochiometric dissolution of CAPs35,36 whereby
surface recrystallization of more stable phases under the given conditions hinders dissolution
of the less stable underlying phase by shielding it from the undersaturated solution. This
incongruent dissolution owing to which particles, effectively, act as buffers against their
own dissolution is not necessarily an undesirable phenomenon since it prolongs the retention
of the material in the target zone, while promoting the rapid initial degradation period and
drug release through which the minimal concentration for inhibiting the bacterial growth is
rapidly exceeded. Incongruency upon dissolution has also implied that even for samples
equilibrated for 19 months, the solubility differed depending on the amount of solid phase
added to a given volume of the solvent37. To minimize the effects of reprecipitation, the
dissolution experiments were carried out by means of daily replacement of the solution
media, as opposed to standard methods involving the usage of a constant solution
throughout prolonged periods of time. Such solubility measurements can also be said to
better mimic in vivo effects of dynamic circulation flow than the static ones.
The results of the second dissolution test that involved a gradual decrease in pH and
relatively short equilibration periods are shown in Fig.4d. The same trend of dissolution
capacity increase from HAP to ACP to DCPA to MCPM was confirmed during this test.
During the dissolution of DCPA, at pH 6.2 and DS = 9 – 11, a re-precipitation event of
thermodynamically the most stable CAP phase to precipitate under these conditions, HAP,
was detected. Due to intrinsic alkalinity of HAP, crystallization of this barely stable new
J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.
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phase lowers pH and speeds up its own dissolution; hence, at pH 4.6, [Ca2+] reaches 5.8
mM, much higher than 4.4 mM at pH 6.6. The broad time scale of the degradation of CAP
phases synthesized in this study, ranging from a few hours to a couple of months or longer,
offers promises for designing the desirable drug release kinetic profiles by mixing these
powders in different ratios.
Fig.3c has illustrated the transition that CAP nanoparticles underwent during desiccation:
aggregation into compact microsized blocks. The naturally rough surface of CAP particles
exhibits topographic irregularities on the atomic scale38,39, which does not only favor
protein adsorption40, osteoblast differentiation41 and expression of osteogenic markers42,
but also causes high levels of adhesion upon contact, promoting facile formation and
retention of stable aggregates even under relatively intensive agitations in the solution. This
propensity of the particles to form aggregates subsequently stable in solution was used as the
primary mechanism for loading the powders with small organic molecules. Aside from the
fact that aggregation can protect the adsorbed drug against degradation, it has also proven to
be a vital means for sustaining the gradual release of the pharmaceutics when the material is
brought into contact with aqueous solution.
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Post-precipitation addition of adsorbate in the form of BSA, one of two model drug
compounds used, was shown to yield greater loading efficiency than co-precipitation of
CAP and the organic molecules (Fig.5). It is assumed that BSA sequesters free Ca2+ ions
and inhibits the nucleation of HAP, as previously observed43,44 and evidenced by visually
delayed onset of precipitation during the dropwise addition of the HxPO4x-3 solution as well
as lesser turbidity of the resulting CAP sol with BSA present in the Ca2+ solution. The
visible comparison of the two precipitates at the titration endpoint has thus shown a larger
amount of particles formed when precipitation was performed in the absence of BSA. In
contrast, BSA, utilized in biochemistry labs as a nonspecific binding agent, binds well to
most surfaces. Once the particles are formed, its binding, owing to an already existing
surface, thus proceeds much more effectively. In contrast, the loading efficiency for
fluorescein was the same, regardless of whether the drug was added to solution before the
precipitation of HAP or after it (Fig.5). Post-precipitation BSA adsorption efficiency for
HAP was by almost two orders of magnitude higher than for fluorescein, which can be
explained by the very high potential of HAP to bind proteins, the reason for which it has
been used as an adsorbent of peptides and nucleic acids in chromatographic columns45,46.
Co-precipitation adsorption efficiency was, on the other hand, almost equal for BSA and
fluorescein on HAP. Since Ca2+ ions present primary binding ions on CAP surface, BSA,
comprising Ca2+-binding amino acid residues along its sequence47, tends to be attracted to it
more specifically than fluorescein. The difference between ζ-potentials of HAP and BSA is,
more or less, constant in the entire pH range of their mutual stability (4 – 10; Fig.6), which
indicates that efficient electrostatically driven adsorption could occur independently of pH.
As demonstrated earlier, owing to alternation of charged Ca2+ and PO43− ions of CAP
surface, the latter adsorbs both acidic and alkaline proteins, regardless of its actual ζpotential and net charge.48 Like BSA, fluorescein also exhibits negative charge at pH > 5
due to the presence of a carboxyl group (pKa ≈ 5) and a phenol group (pKa ≈ 6.4)49, which
favors its attraction to Ca2+ ions on CAP surface.
As could be seen from Fig.7a–b, the trend in the release rate of two model drug compounds
encapsulated within CAP powders tends to be the same as the one observed for the
dissolution rate of the given powders. The release of both drugs from MCPM thus reaches
completion in 1–2 h; fluorescein release from DCPA is practically complete after a week
and reaches 80 % after 10 days for BSA; the drug release from ACP reaches 70 % after 10
days for fluorescein and 50 % for BSA; the released amount of both drugs from HAP is
approximately 30 – 40 % after 10 days. This indicates that the kinetics of the degradation of

J Biomed Mater Res A. Author manuscript; available in PMC 2014 May 01.

Uskoković and Desai

Page 8

NIH-PA Author Manuscript

the carrier greatly determines the temporal profile of the release of the drug. The amount of
the released drug in percentages still exceeds that of the dissolved material, which coincides
with the organic molecules being adsorbed on the surface of the particle rather than being
encapsulated internally, in pores and crystalline crevices. The rate of release of fluorescein
was higher at any time point and for all CAP phases than that of BSA, which can be
explained by its lower adsorption intensity, inversely proportional to desorption propensity
which kinetically precedes the release of the drug. Fluorescein release rate also
exponentially decreases, while BSA release is more continuous, additionally speaking in
favor of BSA being adsorbed more intensively and the release of fluorescein being caused
by undersaturation effect to a greater extent. Fig.7c shows a drastic difference in time
release profiles for fluorescein from dried and undried ACP powders and a negligible one
for BSA. The release of fluorescein from undried ACP is markedly faster, which is due to
the lack of formation of firm aggregates, a consequence of the omitted compaction of
nanoparticles during their desiccation. In contrast, the release kinetics of BSA does not
significantly change depending on whether it is released from dry and dense powders or
undried and loose ones where nanoparticles retained their individual nature, indicating that
the release of BSA is conditioned by the kinetics of its resorption from CAP surface, while
sustained fluorescein release is contingent upon particle aggregation during drying.
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The driving force for the dissolution of the powders and the release of the drug is naturally
undersaturation of the liquid medium with respect to the ionic species that comprise the
solid phase, while the reason for the decrease in the rate of release over time is presumably
partly due to the amorphous and easily soluble content of the powder on the particle surface
as well as to the drug molecules weakly adsorbed on it. Once the drug release becomes
solely contributed to by the internally confined drug molecules, the release mechanism
becomes governed by the complex relationship between the pore size in the material, its
degradation rate, the size of the outwardly diffusing molecules and their binding energy,
which is known to often result in zero-order kinetics.50 Finally, from the standpoint of
antibiotic therapy for osteomyelitis, typically lasting for six weeks5, the most prospective
CAP powder is ACP with its release time scale for a small organic molecule, the same
category to which antibiotics belong, of 1 – 2 months under the conditions applied in our
experiments.

Summary
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The ongoing trend of increase in the number of infectious bone diseases, along with the
imperfect state-of-the-art therapies, highlights the need for finding convenient new ways for
their treatment. Steps towards developing a bioactive nanostructured material for
simultaneous (a) controlled and sustained drug delivery and (b) remineralization of hard
tissue lost to disease are presented in this report. In this work, the emphasis was on the
synthesis of biocompatible and osteoconductive drug delivery carriers with tunable
degradation and drug release kinetics. In the past and with respect to the broad spectrum of
phase compositions of CAPs, only two CAP phases were utilized for the sake of controlling
the biodegradation rate of monophasic or biphasic mixtures thereof: HAP and TCP. In
particular, the approach to bone regeneration by means of surgical implantation of synthetic
calcium phosphates has paradigmatically relied on HAP, the CAP phase already present in
bone. In this study, we have focused on four different phases, alongside HAP, and a much
broader range of solubilities, from pKsp = 1 to pKsp = 117. A set of monophasic CAP
powders with solubilities and corresponding drug release time scales ranging from 1–2 h to
1–2 years was thus synthesized. The sustained release of two model drugs, BSA and
fluorescein, was shown to be directly relatable to the degradation rate of CAP carriers.
Efficient loading of BSA by physisorption and its sustained release were shown to be
independent of the drying-induced aggregation of CAP nanoparticles into larger blocks,
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which the prolonged release and loading of fluorescein was shown to be contingent upon. In
theory, by combining these different CAP phases in various proportions, drug release
profiles could be tailored to the therapeutic occasion. By varying the phase composition of
the particles, an optimal balance between bioactivity and biodegradability could be
achieved, so as to provide an osteoconductive surface for osteoblasts to adhere onto and
match the rather slow rate of the formation of new bone, while at the same time ensuring
sufficient degradation and drug release rates to eradicate the pathological source of infection
and provide ionic species that will serve as ingredients of the newly forming bony tissues.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig.1.
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(a) A double logarithmic curve showing literature-derived solubility products (Ksp) for
different CAP phases synthesized; (b) X-ray diffractograms of five different monophasic
CAP powders prepared: MCPM, DCPA, ACP, HAP, and CPP. Crystallographic planes
corresponding to the given phases are labeled with the following symbols: MCPM - ▲;
DCPA – ■; HAP - ●; CPP - +.
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Fig.2.

X-ray diffractograms of CAP powders synthesized by means of the precipitation method
used to prepare HAP at different pHs of the initial Ca(NO3)2 solution (x→) and of the
solution in equilibrium with the precipitate (→x), without (a) and with (b) the boiling step
following mixing of the reactants. Crystallographic planes corresponding to HAP and DCPA
are labeled with the following symbols: DCPA – ■; HAP - ●.
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Fig.3.
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(a, b) SEM images of DCPA powder prepared with (a) and without (b) the boiling treatment
as a synthesis step; (c) nanosized spherical particles of HAP acting as subunits in
microscopic blocks of material formed by aggregation during desiccation of the powder;
SEM images showing spherical morphologies of monophasic and nanosized CAP powders
other than HAP and DCPA: (d) ACP; (e) MCPM; (f) CPP.
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Fig.4.
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Percentage of the dissolved CAP as a function of the incubation time at pHs 7.4 (a) and 6.0
(b); (c) cumulative increase in the concentration of calcium ions in the supernatant over
time, directly indicative of solubility of the compound, for CPP, ACP and HAP; and (d)
concentration of free Ca2+ ions, directly indicative of the compound’s solubility, as a
function of pH in solutions over different solid CAP phases.
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Fig.5.

Visual appearance of HAP powders loaded with BSA (a, b) and fluorescein (c, d) using the
co-precipitation (a, c) and post-precipitation method (b, d), along with the respective loading
efficiencies.
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Fig.6.

Zeta potential vs. pH curves for BSA and fresh HAP precipitates from aqueous solution,
denoting isoelectric points (IEP) determined for both.
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Fig.7.

Time release profiles for BSA (a) and fluorescein (b) encapsulated within CAP powders of
different phase composition, and a comparison between time release profiles for BSA and
fluorescein molecules encapsulated within dried/agglomerated and undried/nonagglomerated ACP powders (c). Data points are given as averages with error bars
representing the standard deviation.
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Main CAP phases.13–16
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Phase

Chemical formula

Space group

pKsp at 37 °C

Ca/P molar ratio

MCPA*

Ca(H2PO4)2

Triclinic Pī

1.14

0.5

MCPM*

Ca(H2PO4)2·H2O

Triclinic Pī

1.14

0.5

DCPD*

CaHPO4·2H2O

Monoclinic Ia

6.6

1

DCPA*

CaHPO4

Triclinic Pī

7.0

1

β-CPP*

Ca2P2O7

Tetragonal P41

18.5

1

ACP*

Ca3(PO4)2·nH2O

/

25

1.3–1.5

α-TCP*

Ca3(PO4)2

Monoclinic P21/a

25.5

1.5

β-TCP*

Ca3(PO4)2

Rhombohedral R3cH

29.5

1.5

TTCP*

Ca4(PO4)2O

Monoclinic P21

37.5

2

OCP*

Ca8H2(PO4)6·5H2O

Triclinic Pī

97.4

1.33

HAP*

Ca10(PO4)6(OH)2

Pseudo-Hexagonal P63/m

117.3

1.67

*

MCPA = monocalcium phosphate anhydrous; MCPM = monocalcium phosphate monohydrate; DCPD = dicalcium phosphate dehydrate; DCPA =
dicalcium phosphate anhydrous; CPP = calcium pyrophosphate; ACP = amorphous calcium phosphate (data pertain to the phase obtainable at pH 9
– 11); TCP = tricalcium phosphate; TTCP = tetracalcium phosphate; OCP = octacalcium phosphate; HAP = hydroxyapatite.
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0.1

0.1

0.5

0.2

0.33

0.33

1.8

HAP

HAP

ACP

β-CPP*

DCPA

DCPA

MCPM

6.2

6.8

6.8

11.2

6.8

11.5

11.5

pH of
Ca2+(aq)

3.5

0.25

0.25

0.15

0.2

0.06

0.06

[HxPO43-x]
(M)

0.25

7.6

7.6

6.8

10.5

10.5

10.5

(aq)

pH of HxPO43-x

0.1

5.0

5.0

6.0

10.0

10.3

10.3

Final
pH

No

No

Yes

No

No

No

Yes

Boiling

CPP was prepared by thermal annealing at 800 °C in air for 2 h following precipitation.

*

[Ca2+]
(M)

Phase

3

33

59

16

/

18

12

d (nm)

Initial ionic concentrations during the synthesis of CAP powders of different monophase compositions by precipitation at different pHs and temperatures.
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10
10

7.4

7.4

7.4

6.0

6.0

6.0

6.0

ACP

DCPA

MCPM

HAP

ACP

DCPA

MCPM

3.7

5.8

3.7

3.7

0.3

0.15

0.03

3.7

0.84

0.1

0.025

Dissolution rate
([Ca2+]/day) (mM)

Extrapolation of 1 h medium replacement

**

24 h medium replacement

*

10

7.4

HAP

5.8

10

pH

Phase

[Ca2+]total

100

5.2

1.5

0.3

100

14.5

1

0.25

Dissolution rate
(%CAP/day)

Time to complete
dissolution**
≈ 2 months
≈ 1 week
≈ 10 h
≈ 1–2 h
≈ 2 months
≈ 2 weeks
≈ 3 days
≈ 1–2 h

Time to complete
dissolution*
≈ 1 year
≈ 3 months
≈ 1 week
≈ 1–2 h
≈ 1 year
≈ 2 months
≈ 2–3 weeks
≈ 1–2 h

Dissolution time scales and rates for four different CAP powders: HAP, ACP, DCPA and MCPM at two different pHs: 7.4 and 6.0.
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